Amsler Grid Eye Test
Vascular endothelial growth factor (VEGF) inhibitors for ophthalmic use: Aflibercept (Eylea) and Ranibizumab (Lucentis)
Bevacizumab (Avastin) is not FDA-approved for use in ophthalmic indications; however, a large body of medical literature supports its use in several ophthalmic indications. Avastin is injected every 4-6 weeks. When used for these indications, bevacizumab must be compounded. The use of pharmacies following the United States Pharmacopeia (USP) Chapter 797 requirements for compounding sterile preparations is recommended.
Aflibercept (Eylea, also known as VEGF-Trap Eye) - provides another vascular endothelial growth factor inhibitor for neovascular (wet) age-related macular degeneration and mascular edema following central retinal vein occulsion. Aflibercept acts as a soluble decoy receptor that binds VEGF and thereby can inhibit the binding and activation of VEGF receptors. Eylea is injected every 4-8 weeks.
Ranibizumab (Lucentis) - indicated for the treatment of patients with:
- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion
- Diabetic macular edema.
Lucentis is injected every 4 weeks.
Pegaptanib (Macugen) - indicated for the treatment of patients with Neovascular (wet) age-related macular degeneration (AMD).
Macugen is injected every 4-6 weeks.
Ranibizumab Lucentis 樂舒晴 priceBevacizumab Avastin 癌思停 price
Macular hole, Retinal Diagnostic Center
Northern California Retina Vitreous Associates Medical Group El Camino: Rahul Khurana, *Alok Bansal, Edwin Boldrey, *Jesus Borrillo, Louis Chang, *James Palmer, Mark Wieland,
Retinal Diagnostic Center, Clement Chow, Di Salvo Howard Chen, Amr Dessouki, Patrick Monahan, Brian Ward,
South Bay Retina, Keshav Narain Sunnyvale, Optical Coherence Tomography (OCT)
Gloria Wu, Samaritan
No comments:
Post a Comment